Entre alacranes y espejismos. análisis de la crónica literaria la hembra del alacrán: amor y traición en los carteles de Juan Carlos Giraldo, desde los conceptos de Pierre Bourdieu (Habitus, Campo e Illusio)

El presente trabajo es una investigación de tipo crítica lieraria, la cual tiene como propósito analizar las representaciones sociales que se construyen en torno a la figura del hombre y la mujer, desde los conceptos de Habitus, Campo e Illusio, del sociólogo y antropólogo francés, Pierre Bourdieu; en la novela La hembra del Alacrán: Amor y traición en los carteles (2014), escrita por el periodista y editor judicial de RCN Juan Carlos Giraldo, un libro polémico que ha sido éxito en ventas, con tres ediciones en su primer año, perteneciente a “la narco narrativa”, en el que se evidencian temas como, la violencia, el narcotráfico y las drogas, las cuales han contribuido a la construcción de estereotipos y prácticas culturales centradas en el dinero como fin de todos los medios

Recorrido histórico de las prácticas del lenguaje en la significación de las representaciones sociales del habitante de calle

El presente proyecto de investigación tiene como fin realizar un estudio sobre las diferentes formas de lenguaje utilizadas para denominar a los habitantes de calle que para efecto de este documento se asume como “persona cuya vida se desenvuelve fundamentalmente en la calle, como espacio físico-social donde resuelve necesidades vitales, construye relaciones afectivas y mediaciones socio-culturales estructurando un estilo de vida“. (Estudio previo Conveniencia y Oportunidad Centro de Atención Habitante de Calle, p3, Universidad de Antioquia, 2006.). Por lo tanto se analizará de manera minuciosa la terminología o la denominación utilizada por la población en general para identificar a dichos sujetos; para esto es necesario recurrir al estudio de los antecedentes y la epistemología de los vocablos o estereotipos que servirá para describir de forma cronológica las prácticas de lenguaje y la significación de cada uno. Se busca también identificar los factores sociales y demás variables que inciden en la utilización de dichos términos, variables y factores que se irán descubriendo en el proceso de la investigación; a partir de esto es pertinente que a través de este proyecto de investigación se resalté la importancia que la población Colombiana reconozca de forma respetuosa y digna al habitante de calle

Fístula colovesical secundaria a diverticulitis complicada: tratamiento laparoscópico. Reporte de caso

Introduction: The colovesical fistula is a junction between the urinary bladder and the large intestine. It occurs in 2% of patients with diverticular disease of the colon and generates symptoms such as pneumaturia and fecaluria associated with recurrent urinary tract infections. The patients are diagnosed by imaging studies and their treatment is usually surgical.   Objective: To report the laparoscopic treatment administered to a patient that presented a case of colovesical fistula secondary to severe diverticulitis. Case report: The case of a 69-year-old male patient with a medical record of diverticular disease, who presented recurrent urinary tract infection, fecaluria, and pneumaturia is presented. The cystoscopy procedure showed no signs of anal fistula, and the abdominopelvic tomography showed signals of inflammations and colovesical fistula associated with complicated diverticulitis. During the laparoscopic procedure, a pericolic abscess was found without evidence of anal fistula. Drainage and suture of the colon and omentum interposition were performed without presenting intestinal resection. The patient had an adequate postoperative recovery and was discharged on the sixth day. The aim of this surgical treatment is focused on the control of medical complications caused by diverticulitis, in this case, colovesical fistula. Conclusions: This procedure is minimally invasive, and it is associated with a faster functional recovery since it does not present the morbidity of a colon resection or colostomy.  Introducción: La fístula colovesical es la unión entre la vejiga y el intestino grueso, se presenta en el 2% de los pacientes con enfermedad diverticular del colon, genera síntomas como neumaturia y fecaluria, asociados a infecciones urinarias recurrentes. Los pacientes se diagnostican mediante estudios imagenológicos y su tratamiento generalmente es quirúrgico.  Objetivo: Reportar el caso   de  tratamiento laparoscópico  de paciente con  fístula colovesical secundaria a diverticulitis complicada. Caso clínico: Se presenta el caso de un paciente masculino de 69 años, con antecedente de enfermedad diverticular, cursando con infección de vías urinarias recurrentes, fecaluria y neumaturia. La cistoscopia no mostró trayecto fistuloso y la tomografía abdominopélvica mostró hallazgos inflamatorios y fístula colovesical asociada a diverticulitis complicada. Durante procedimiento laparoscópico se encuentra absceso pericólico sin evidencia del trayecto fistuloso, se realizó drenaje, sutura del colon e interposición del epiplón, sin resección intestinal. Paciente con adecuada evolución postoperatoria con egreso al sexto día. El objetivo del tratamiento quirúrgico se centra en el control de complicaciones generadas por los divertículos, en este caso, la fístula colovesical. Conclusiones: El procedimiento laparoscópico es de mínima invasión, no presenta la morbilidad que implica una resección de colon o una colostomía y  se asocia con una recuperación funcional más rápida. &nbsp

Fístula colovesical secundaria a diverticulitis complicada: tratamiento laparoscópico. Reporte de caso

Introduction: The colovesical fistula is a junction between the urinary bladder and the large intestine. It occurs in 2% of patients with diverticular disease of the colon and generates symptoms such as pneumaturia and fecaluria associated with recurrent urinary tract infections. The patients are diagnosed by imaging studies and their treatment is usually surgical.   Objective: To report the laparoscopic treatment administered to a patient that presented a case of colovesical fistula secondary to severe diverticulitis. Case report: The case of a 69-year-old male patient with a medical record of diverticular disease, who presented recurrent urinary tract infection, fecaluria, and pneumaturia is presented. The cystoscopy procedure showed no signs of anal fistula, and the abdominopelvic tomography showed signals of inflammations and colovesical fistula associated with complicated diverticulitis. During the laparoscopic procedure, a pericolic abscess was found without evidence of anal fistula. Drainage and suture of the colon and omentum interposition were performed without presenting intestinal resection. The patient had an adequate postoperative recovery and was discharged on the sixth day. The aim of this surgical treatment is focused on the control of medical complications caused by diverticulitis, in this case, colovesical fistula. Conclusions: This procedure is minimally invasive, and it is associated with a faster functional recovery since it does not present the morbidity of a colon resection or colostomy.  Introducción: La fístula colovesical es la unión entre la vejiga y el intestino grueso, se presenta en el 2% de los pacientes con enfermedad diverticular del colon, genera síntomas como neumaturia y fecaluria, asociados a infecciones urinarias recurrentes. Los pacientes se diagnostican mediante estudios imagenológicos y su tratamiento generalmente es quirúrgico.  Objetivo: Reportar el caso   de  tratamiento laparoscópico  de paciente con  fístula colovesical secundaria a diverticulitis complicada. Caso clínico: Se presenta el caso de un paciente masculino de 69 años, con antecedente de enfermedad diverticular, cursando con infección de vías urinarias recurrentes, fecaluria y neumaturia. La cistoscopia no mostró trayecto fistuloso y la tomografía abdominopélvica mostró hallazgos inflamatorios y fístula colovesical asociada a diverticulitis complicada. Durante procedimiento laparoscópico se encuentra absceso pericólico sin evidencia del trayecto fistuloso, se realizó drenaje, sutura del colon e interposición del epiplón, sin resección intestinal. Paciente con adecuada evolución postoperatoria con egreso al sexto día. El objetivo del tratamiento quirúrgico se centra en el control de complicaciones generadas por los divertículos, en este caso, la fístula colovesical. Conclusiones: El procedimiento laparoscópico es de mínima invasión, no presenta la morbilidad que implica una resección de colon o una colostomía y  se asocia con una recuperación funcional más rápida. &nbsp

Recent trends in management strategies for two major maize borers: Ostrinia nubilalis and Sesamia nonagrioides

23 p.-2 tab.Stem borers (Lepidoptera) are common cereal pests. In many parts of the world, the species Ostrinia nubilalis and Sesamia nonagrioides stand out as important insect pests of economically important crops such as maize. Their management relied mainly on transgenic host plant resistance over the last 25 years. Technologies based on the insecticidal properties of Bacillus thuringiensis-derived proteins allowed widespread pest population suppression, especially for O. nubilalis. However, the recent discovery of Bt resistance, which has revitalized interest in both pests’ biology and management, may jeopardize the effectiveness of such transgenic technologies. Historical information on O. nubilalis bionomy may need to be reassessed in light of changing climate conditions and changing agricultural practices, as well as increased production of alternate host crops across its distribution range. The current paper examines the bioecology and historical research that has been conducted to manage these two important maize-boring pests.N

First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)-Pan-American League of Associations of Rheumatology (PANLAR)

Systemic lupus erythematosus (SLE), a complex and heterogeneous autoimmune disease, represents a significant challenge for both diagnosis and treatment. Patients with SLE in Latin America face special problems that should be considered when therapeutic guidelines are developed. The objective of the study is to develop clinical practice guidelines for Latin American patients with lupus. Two independent teams (rheumatologists with experience in lupus management and methodologists) had an initial meeting in Panama City, Panama, in April 2016. They selected a list of questions for the clinical problems most commonly seen in Latin American patients with SLE. These were addressed with the best available evidence and summarised in a standardised format following the Grading of Recommendations Assessment, Development and Evaluation approach. All preliminary findings were discussed in a second face-to-face meeting in Washington, DC, in November 2016. As a result, nine organ/system sections are presented with the main findings; an 'overarching' treatment approach was added. Special emphasis was made on regional implementation issues. Best pharmacologic options were examined for musculoskeletal, mucocutaneous, kidney, cardiac, pulmonary, neuropsychiatric, haematological manifestations and the antiphospholipid syndrome. The roles of main therapeutic options (ie, glucocorticoids, antimalarials, immunosuppressant agents, therapeutic plasma exchange, belimumab, rituximab, abatacept, low-dose aspirin and anticoagulants) were summarised in each section. In all cases, benefits and harms, certainty of the evidence, values and preferences, feasibility, acceptability and equity issues were considered to produce a recommendation with special focus on ethnic and socioeconomic aspects. Guidelines for Latin American patients with lupus have been developed and could be used in similar settings.Fil: Pons Estel, Bernardo A.. Centro Regional de Enfermedades Autoinmunes y Reumáticas; ArgentinaFil: Bonfa, Eloisa. Universidade de Sao Paulo; BrasilFil: Soriano, Enrique R.. Instituto Universitario Hospital Italiano de Buenos Aires. Rectorado.; ArgentinaFil: Cardiel, Mario H.. Centro de Investigación Clínica de Morelia; MéxicoFil: Izcovich, Ariel. Hospital Alemán; ArgentinaFil: Popoff, Federico. Hospital Aleman; ArgentinaFil: Criniti, Juan M.. Hospital Alemán; ArgentinaFil: Vásquez, Gloria. Universidad de Antioquia; ColombiaFil: Massardo, Loreto. Universidad San Sebastián; ChileFil: Duarte, Margarita. Hospital de Clínicas; ParaguayFil: Barile Fabris, Leonor A.. Hospital Angeles del Pedregal; MéxicoFil: García, Mercedes A.. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; ArgentinaFil: Amigo, Mary Carmen. Centro Médico Abc; MéxicoFil: Espada, Graciela. Gobierno de la Ciudad de Buenos Aires. Hospital General de Niños "Ricardo Gutiérrez"; ArgentinaFil: Catoggio, Luis J.. Hospital Italiano. Instituto Universitario. Escuela de Medicina; ArgentinaFil: Sato, Emilia Inoue. Universidade Federal de Sao Paulo; BrasilFil: Levy, Roger A.. Universidade do Estado de Rio do Janeiro; BrasilFil: Acevedo Vásquez, Eduardo M.. Universidad Nacional Mayor de San Marcos; PerúFil: Chacón Díaz, Rosa. Policlínica Méndez Gimón; VenezuelaFil: Galarza Maldonado, Claudio M.. Corporación Médica Monte Sinaí; EcuadorFil: Iglesias Gamarra, Antonio J.. Universidad Nacional de Colombia; ColombiaFil: Molina, José Fernando. Centro Integral de Reumatología; ColombiaFil: Neira, Oscar. Universidad de Chile; ChileFil: Silva, Clóvis A.. Universidade de Sao Paulo; BrasilFil: Vargas Peña, Andrea. Hospital Pasteur Montevideo; UruguayFil: Gómez Puerta, José A.. Hospital Clinic Barcelona; EspañaFil: Scolnik, Marina. Instituto Universitario Hospital Italiano de Buenos Aires. Rectorado.; ArgentinaFil: Pons Estel, Guillermo J.. Centro Regional de Enfermedades Autoinmunes y Reumáticas; Argentina. Hospital Provincial de Rosario; ArgentinaFil: Ugolini Lopes, Michelle R.. Universidade de Sao Paulo; BrasilFil: Savio, Verónica. Instituto Universitario Hospital Italiano de Buenos Aires. Rectorado.; ArgentinaFil: Drenkard, Cristina. University of Emory; Estados UnidosFil: Alvarellos, Alejandro J.. Hospital Privado Universitario de Córdoba; ArgentinaFil: Ugarte Gil, Manuel F.. Universidad Cientifica del Sur; Perú. Hospital Nacional Guillermo Almenara Irigoyen; PerúFil: Babini, Alejandra. Instituto Universitario Hospital Italiano de Buenos Aires. Rectorado.; ArgentinaFil: Cavalcanti, André. Universidade Federal de Pernambuco; BrasilFil: Cardoso Linhares, Fernanda Athayde. Hospital Pasteur Montevideo; UruguayFil: Haye Salinas, Maria Jezabel. Hospital Privado Universitario de Córdoba; ArgentinaFil: Fuentes Silva, Yurilis J.. Universidad de Oriente - Núcleo Bolívar; VenezuelaFil: Montandon De Oliveira E Silva, Ana Carolina. Universidade Federal de Goiás; BrasilFil: Eraso Garnica, Ruth M.. Universidad de Antioquia; ColombiaFil: Herrera Uribe, Sebastián. Hospital General de Medellin Luz Castro de Gutiérrez; ColombiaFil: Gómez Martín, DIana. Instituto Nacional de la Nutrición Salvador Zubiran; MéxicoFil: Robaina Sevrini, Ricardo. Universidad de la República; UruguayFil: Quintana, Rosana M.. Hospital Provincial de Rosario; Argentina. Centro Regional de Enfermedades Autoinmunes y Reumáticas; ArgentinaFil: Gordon, Sergio. Hospital Interzonal General de Agudos Dr Oscar Alende. Unidad de Reumatología y Enfermedades Autoinmunes Sistémicas; ArgentinaFil: Fragoso Loyo, Hilda. Instituto Nacional de la Nutrición Salvador Zubiran; MéxicoFil: Rosario, Violeta. Hospital Docente Padre Billini; República DominicanaFil: Saurit, Verónica. Hospital Privado Universitario de Córdoba; ArgentinaFil: Appenzeller, Simone. Universidade Estadual de Campinas; BrasilFil: Dos Reis Neto, Edgard Torres. Universidade Federal de Sao Paulo; BrasilFil: Cieza, Jorge. Hospital Nacional Edgardo Rebagliati Martins; PerúFil: González Naranjo, Luis A.. Universidad de Antioquia; ColombiaFil: González Bello, Yelitza C.. Ceibac; MéxicoFil: Collado, María Victoria. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Médicas; ArgentinaFil: Sarano, Judith. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Médicas; ArgentinaFil: Retamozo, Maria Soledad. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones en Ciencias de la Salud. Universidad Nacional de Córdoba. Instituto de Investigaciones en Ciencias de la Salud; ArgentinaFil: Sattler, María E.. Provincia de Buenos Aires. Ministerio de Salud. Hospital Interzonal de Agudos "Eva Perón"; ArgentinaFil: Gamboa Cárdenas, Rocio V.. Hospital Nacional Guillermo Almenara Irigoyen; PerúFil: Cairoli, Ernesto. Universidad de la República; UruguayFil: Conti, Silvana M.. Hospital Provincial de Rosario; ArgentinaFil: Amezcua Guerra, Luis M.. Instituto Nacional de Cardiologia Ignacio Chavez; MéxicoFil: Silveira, Luis H.. Instituto Nacional de Cardiologia Ignacio Chavez; MéxicoFil: Borba, Eduardo F.. Universidade de Sao Paulo; BrasilFil: Pera, Mariana A.. Hospital Interzonal General de Agudos General San Martín; ArgentinaFil: Alba Moreyra, Paula B.. Universidad Nacional de Córdoba. Facultad de Medicina; ArgentinaFil: Arturi, Valeria. Hospital Interzonal General de Agudos General San Martín; ArgentinaFil: Berbotto, Guillermo A.. Provincia de Buenos Aires. Ministerio de Salud. Hospital Interzonal de Agudos "Eva Perón"; ArgentinaFil: Gerling, Cristian. Hospital Interzonal General de Agudos Dr Oscar Alende. Unidad de Reumatología y Enfermedades Autoinmunes Sistémicas; ArgentinaFil: Gobbi, Carla Andrea. Universidad Nacional de Córdoba. Facultad de Medicina; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Gervasoni, Viviana L.. Hospital Provincial de Rosario; ArgentinaFil: Scherbarth, Hugo R.. Hospital Interzonal General de Agudos Dr Oscar Alende. Unidad de Reumatología y Enfermedades Autoinmunes Sistémicas; ArgentinaFil: Brenol, João C. Tavares. Hospital de Clinicas de Porto Alegre; BrasilFil: Cavalcanti, Fernando. Universidade Federal de Pernambuco; BrasilFil: Costallat, Lilian T. Lavras. Universidade Estadual de Campinas; BrasilFil: Da Silva, Nilzio A.. Universidade Federal de Goiás; BrasilFil: Monticielo, Odirlei A.. Hospital de Clinicas de Porto Alegre; BrasilFil: Seguro, Luciana Parente Costa. Universidade de Sao Paulo; BrasilFil: Xavier, Ricardo M.. Hospital de Clinicas de Porto Alegre; BrasilFil: Llanos, Carolina. Universidad Católica de Chile; ChileFil: Montúfar Guardado, Rubén A.. Instituto Salvadoreño de la Seguridad Social; El SalvadorFil: Garcia De La Torre, Ignacio. Hospital General de Occidente; MéxicoFil: Pineda, Carlos. Instituto Nacional de Rehabilitación; MéxicoFil: Portela Hernández, Margarita. Umae Hospital de Especialidades Centro Medico Nacional Siglo Xxi; MéxicoFil: Danza, Alvaro. Hospital Pasteur Montevideo; UruguayFil: Guibert Toledano, Marlene. Medical-surgical Research Center; CubaFil: Reyes, Gil Llerena. Medical-surgical Research Center; CubaFil: Acosta Colman, Maria Isabel. Hospital de Clínicas; ParaguayFil: Aquino, Alicia M.. Hospital de Clínicas; ParaguayFil: Mora Trujillo, Claudia S.. Hospital Nacional Edgardo Rebagliati Martins; PerúFil: Muñoz Louis, Roberto. Hospital Docente Padre Billini; República DominicanaFil: García Valladares, Ignacio. Centro de Estudios de Investigación Básica y Clínica; MéxicoFil: Orozco, María Celeste. Instituto de Rehabilitación Psicofísica; ArgentinaFil: Burgos, Paula I.. Pontificia Universidad Católica de Chile; ChileFil: Betancur, Graciela V.. Instituto de Rehabilitación Psicofísica; ArgentinaFil: Alarcón, Graciela S.. Universidad Peruana Cayetano Heredia; Perú. University of Alabama at Birmingahm; Estados Unido

Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension

OBJECTIVE: To evaluate whether eculizumab helps patients with anti-acetylcholine receptor-positive (AChR+) refractory generalized myasthenia gravis (gMG) achieve the Myasthenia Gravis Foundation of America (MGFA) post-intervention status of minimal manifestations (MM), we assessed patients' status throughout REGAIN (Safety and Efficacy of Eculizumab in AChR+ Refractory Generalized Myasthenia Gravis) and its open-label extension. METHODS: Patients who completed the REGAIN randomized controlled trial and continued into the open-label extension were included in this tertiary endpoint analysis. Patients were assessed for the MGFA post-intervention status of improved, unchanged, worse, MM, and pharmacologic remission at defined time points during REGAIN and through week 130 of the open-label study. RESULTS: A total of 117 patients completed REGAIN and continued into the open-label study (eculizumab/eculizumab: 56; placebo/eculizumab: 61). At week 26 of REGAIN, more eculizumab-treated patients than placebo-treated patients achieved a status of improved (60.7% vs 41.7%) or MM (25.0% vs 13.3%; common OR: 2.3; 95% CI: 1.1-4.5). After 130 weeks of eculizumab treatment, 88.0% of patients achieved improved status and 57.3% of patients achieved MM status. The safety profile of eculizumab was consistent with its known profile and no new safety signals were detected. CONCLUSION: Eculizumab led to rapid and sustained achievement of MM in patients with AChR+ refractory gMG. These findings support the use of eculizumab in this previously difficult-to-treat patient population. CLINICALTRIALSGOV IDENTIFIER: REGAIN, NCT01997229; REGAIN open-label extension, NCT02301624. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that, after 26 weeks of eculizumab treatment, 25.0% of adults with AChR+ refractory gMG achieved MM, compared with 13.3% who received placebo

Minimal Symptom Expression' in Patients With Acetylcholine Receptor Antibody-Positive Refractory Generalized Myasthenia Gravis Treated With Eculizumab

The efficacy and tolerability of eculizumab were assessed in REGAIN, a 26-week, phase 3, randomized, double-blind, placebo-controlled study in anti-acetylcholine receptor antibody-positive (AChR+) refractory generalized myasthenia gravis (gMG), and its open-label extension

Impact of COVID-19 on cardiovascular testing in the United States versus the rest of the world

Objectives: This study sought to quantify and compare the decline in volumes of cardiovascular procedures between the United States and non-US institutions during the early phase of the coronavirus disease-2019 (COVID-19) pandemic. Background: The COVID-19 pandemic has disrupted the care of many non-COVID-19 illnesses. Reductions in diagnostic cardiovascular testing around the world have led to concerns over the implications of reduced testing for cardiovascular disease (CVD) morbidity and mortality. Methods: Data were submitted to the INCAPS-COVID (International Atomic Energy Agency Non-Invasive Cardiology Protocols Study of COVID-19), a multinational registry comprising 909 institutions in 108 countries (including 155 facilities in 40 U.S. states), assessing the impact of the COVID-19 pandemic on volumes of diagnostic cardiovascular procedures. Data were obtained for April 2020 and compared with volumes of baseline procedures from March 2019. We compared laboratory characteristics, practices, and procedure volumes between U.S. and non-U.S. facilities and between U.S. geographic regions and identified factors associated with volume reduction in the United States. Results: Reductions in the volumes of procedures in the United States were similar to those in non-U.S. facilities (68% vs. 63%, respectively; p = 0.237), although U.S. facilities reported greater reductions in invasive coronary angiography (69% vs. 53%, respectively; p < 0.001). Significantly more U.S. facilities reported increased use of telehealth and patient screening measures than non-U.S. facilities, such as temperature checks, symptom screenings, and COVID-19 testing. Reductions in volumes of procedures differed between U.S. regions, with larger declines observed in the Northeast (76%) and Midwest (74%) than in the South (62%) and West (44%). Prevalence of COVID-19, staff redeployments, outpatient centers, and urban centers were associated with greater reductions in volume in U.S. facilities in a multivariable analysis. Conclusions: We observed marked reductions in U.S. cardiovascular testing in the early phase of the pandemic and significant variability between U.S. regions. The association between reductions of volumes and COVID-19 prevalence in the United States highlighted the need for proactive efforts to maintain access to cardiovascular testing in areas most affected by outbreaks of COVID-19 infection

Optimasi Portofolio Resiko Menggunakan Model Markowitz MVO Dikaitkan dengan Keterbatasan Manusia dalam Memprediksi Masa Depan dalam Perspektif Al-Qur`an

Risk portfolio on modern finance has become increasingly technical, requiring the use of sophisticated mathematical tools in both research and practice. Since companies cannot insure themselves completely against risk, as human incompetence in predicting the future precisely that written in Al-Quran surah Luqman verse 34, they have to manage it to yield an optimal portfolio. The objective here is to minimize the variance among all portfolios, or alternatively, to maximize expected return among all portfolios that has at least a certain expected return. Furthermore, this study focuses on optimizing risk portfolio so called Markowitz MVO (Mean-Variance Optimization). Some theoretical frameworks for analysis are arithmetic mean, geometric mean, variance, covariance, linear programming, and quadratic programming. Moreover, finding a minimum variance portfolio produces a convex quadratic programming, that is minimizing the objective function ðð¥with constraintsð ð 𥠥 ðandð´ð¥ = ð. The outcome of this research is the solution of optimal risk portofolio in some investments that could be finished smoothly using MATLAB R2007b software together with its graphic analysis